Ben Bergo, CEO of Visus, shares data from the company's pivotal phase 3 BRIO-1 trial, as well as answers questions about Brimochol PF.
Ben Bergo
Advertisement
Articles by Ben Bergo
Advertisement
Latest Updated Articles
VEW 2023: Phase 3 BRIO-I data for brimochol PF for presbyopiaSeptember 29th 2023
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Portable vision screener provides accurate clinical assessment for drivers, study finds
2
The Independent Advantage S02 E02: Should you worry about AI replacing you?
3
Study: Adolescents with migraines associated with binocular vision difficulties
4
AMA passes resolution backing formal disease classification for myopia
5